Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One-Shot hybrid procedure takes on stubborn atrial fibrillation

NCT ID NCT02630914

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a single hybrid procedure that combines keyhole surgery with a catheter-based approach to treat complex atrial fibrillation (AF) in 12 patients. The goal was to see if this combined method could completely isolate the abnormal electrical signals in the heart. The approach aims to improve success rates and reduce the need for repeat hospital visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

12 people

The number who actually took part.

Started

Sep 2015

Finished

Mar 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: patients with complex AF defined by the following criteria : * AF\> 1 week or long term persistent\> 1 year * AND Symptomatic * AND after failure of treatment of anti-arrhythmic or against-indication for anti-arrhythmic Exclusion Criteria: The exclusion criteria are relevant contraindications thoracoscopy or the non-complex nature of the AF: * Paroxysmal AF or AF cardioverted anti-arrhythmic test (unless against indicated) * Recent AF for which a simple gesture is intracavitary considered sufficient * Permanent AF * Asymptomatic AF * Very old AF (\> 5 years) or atrial major ectasia (\> 60 mm) * Need another surgery (valve bypass coronary) * Previous history of sternotomy or thoracotomy * High-risk surgical or anesthetic Patient * BMI\> 35 * Sleep Apnea * Ejection fraction \<35% * Thoracic trauma history * Veins Pulmonary stenosis\> 50% * Hyperthyroidism * Thrombus in LAA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Toulouse

    Toulouse, Midi Pyrenees, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.